VICP: Vicapsys Life Sciences, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 14.24
Enterprise Value ($M) 14.73
Book Value ($M) -2.65
Book Value / Share -0.08
Price / Book -5.38
NCAV ($M) -2.65
NCAV / Share -0.08
Price / NCAV -5.38

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -33.98
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.03
Current Ratio 0.03

Balance Sheet (mrq) ($M)
Current Assets 0.09
Assets 0.09
Liabilities 2.74
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)
Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-01-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2024 ☐ Transition Report pursuant to S
2025-01-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2024 ☐ Transition Report pursuant
2025-01-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2024 ☐ Transition Report pursuant to
2024-10-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ Annual Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 ☐ Transition Report pursuant to Secti

(click for more detail)

Similar Companies
VCNX – Vaccinex, Inc. VETOF – Vetoquinol SA
VGLS – VG Life Sciences Inc. VIRX – Viracta Therapeutics, Inc.
VREOF – Vireo Growth Inc.


Financial data and stock pages provided by
Fintel.io